Basic Description

Product Name	Pertuzumab (anti-HER2), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to ERBB2/HER2/CD340, >95%, high purity, Human IgG1
Synonyms	2-Butanol, 1-[(2,3-dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-, [R-(R,S)]- \| Q27078025 \| (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol \| DTXSID401118341 \| SCHEMBL8027938 \| (2R,3S)-1-[(7-methyl-2,3-dih
Specifications & Purity	ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Host species	Human
Specificity	ERBB2/HER2/CD340
Application	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
Conjugation	Unconjugated
Grade	Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type	INHIBITOR
Mechanism of action	Antibody of erb-b2 receptor tyrosine kinase 2
Product Description	Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor. It can be used in the study of metastatic HER2 positive breast cancer. Purity >95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg

Product Properties

Antibody Type	Primary antibody
Clonality	Recombinant
Isotype	Human IgG1
Light Chain Type	kappa
SDS-PAGE	145.44 kDa
Purification Method	Protein A purified
Purity	>95%
Source	CHO supernatant
Form	Liquid
Concentration	Lot by Lot
Storage Temp	Store at -80°C,Avoid repeated freezing and thawing
Shipped In	Ice chest + Ice pads
Stability And Storage	Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS	380610-27-5

Images

Pertuzumab (anti-HER2) (P412000) - Flow Cytometry
Flow Cytometry analysis of MCF-7 cells labelling HER2 (red) with Pertuzumab (anti-HER2) (P412000). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Pertuzumab (anti-HER2) (P412000) - SEC
The purity of Pertuzumab (anti-HER2) (P412000) is more than 95% verified by HPLC.

Pertuzumab (anti-HER2) (P412000) - ELISA
Immobilized HER2-23-652-his at 2 μg/mL can bind Pertuzumab (anti-HER2) (P412000) with the EC₅₀ of 13.75 ng/mL.

Associated Targets(Human)

CYP1A2 Tchem Cytochrome P450 1A2 (1 Activities)

Discover Target: CYP1A2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ERBB2 Tclin Receptor tyrosine-protein kinase erbB-2 (0 Activities)

Discover Target: ERBB2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ADRB2 Tclin Beta-2 adrenergic receptor (2 Activities)

Discover Target: ADRB2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ERBB2 Tclin Receptor protein-tyrosine kinase erbB-2 (7851 Activities)

Discover Target: ERBB2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ERBB2 Tclin Epidermal growth factor receptor and ErbB2 (HER1 and HER2) (186 Activities)

Discover Target: ERBB2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ERBB2 Tclin Epidermal growth factor receptor (487 Activities)

Discover Target: ERBB2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ERBB2 Tclin FASN/HER2 (2 Activities)

Discover Target: ERBB2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mechanisms of Action

Mechanism of Action	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	References

Database links

Wikipedia	Pertuzumab
IMGT/mAb-DB	80
Reactome Reaction	R-HSA-9665726, R-HSA-9665703, R-HSA-9665708
Reactome Drug	R-ALL-9665971

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

2 results found

Lot Number	Certificate Type	Date	Item
ZJ23F0800951	Certificate of Analysis	Sep 04, 2023	P412000
ZJ23F0800952	Certificate of Analysis	Sep 04, 2023	P412000

FAQs and Articles

FAQ

Flow cytometry protocol

Categories: Protocols

Tags:

Antibodies Flow Cytometry Flow Antibodies Reactive dyes Indirect antibody labelling

References

1. Badache A, Hynes NE. (2004) A new therapeutic antibody masks ErbB2 to its partners.. Cancer Cell, 5 (4): (299-301). [PMID:15093533] [10.1021/op500134e]
2. Ferguson KM. (2004) Active and inactive conformations of the epidermal growth factor receptor.. Biochem Soc Trans, 32 (Pt 5): (742-5). [PMID:15494003] [10.1021/op500134e]
3. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX. (2006) Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.. Cancer Immunol Immunother, 55 (6): (717-27). [PMID:16151804] [10.1021/op500134e]
4. Harbeck N, Beckmann MW, Rody A, Schneeweiss A, Müller V, Fehm T, Marschner N, Gluz O, Schrader I, Heinrich G et al.. (2013) HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer.. Breast Care (Basel), 8 (1): (49-55). [PMID:24715843] [10.1021/op500134e]
5. Dumas J, Hatoum-Mokdad H, Sibley RN, Smith RA, Scott WJ, Khire U, Lee W, Wood J, Wolanin D, Cooley J, Bankston D, Redman AM, Schoenleber R, Caringal Y, Gunn D, Romero R, Osterhout M, Paulsen H, Housley TJ, Wilhelm SM, Pirro J, Chien DS, Ranges GE, Shrikhande A, Muzsi A, Bortolon E, Wakefield J, Gianpaolo Ostravage C, Bhargava A, Chau T.. (2002) Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor.. Bioorg Med Chem Lett, 12 (12): (1559-1562). [PMID:12039561] [10.1016/s0960-894x(02)00238-x]
6. Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HD, Winters RT, Denny WA.. (1998) Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.. J Med Chem, 41 (5): (742-751). [PMID:9513602] [10.1021/jm970641d]
7. Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNamara DJ, Dobrusin EM, Bridges AJ, Zhou H, Showalter HD, Winters RT, Leopold WR, Fry DW, Nelson JM, Slintak V, Elliot WL, Roberts BJ, Vincent PW, Patmore SJ.. (1999) Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.. J Med Chem, 42 (10): (1803-1815). [PMID:10346932] [10.1021/jm9806603]
8. Berezov A, Zhang HT, Greene MI, Murali R.. (2001) Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis.. J Med Chem, 44 (16): (2565-2574). [PMID:11472210] [10.1021/jm000527m]
9. Kim KS, Kimball SD, Misra RN, Rawlins DB, Hunt JT, Xiao HY, Lu S, Qian L, Han WC, Shan W, Mitt T, Cai ZW, Poss MA, Zhu H, Sack JS, Tokarski JS, Chang CY, Pavletich N, Kamath A, Humphreys WG, Marathe P, Bursuker I, Kellar KA, Roongta U, Batorsky R, Mulheron JG, Bol D, Fairchild CR, Lee FY, Webster KR.. (2002) Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.. J Med Chem, 45 (18): (3905-3927). [PMID:12190313] [10.1021/jm0201520]
10. Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO.. (2002) Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.. J Med Chem, 45 (6): (1300-1312). [PMID:11881999] [10.1021/jm011022e]
11. Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S et al.. (2012) 7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.. J Med Chem, 55 (1): (403-13). [PMID:22136433] [10.1021/op500134e]
12. Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, Snell G, Jennings A, Iwamoto K, Habuka N, Hirokawa A et al.. (2011) Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.. J Biol Chem, 286 (21): (18756-65). [PMID:21454582] [10.1021/op500134e]
13. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Leahy DJ. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.. Nature, 421 (6924): (756-60). [PMID:12610629] [10.1021/op500134e]
14. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al.. (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res, 14 (10B): (2121-7). [PMID:15489334] [10.1021/op500134e]
15. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E et al.. (2004) Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.. Cancer Res, 64 (11): (3958-65). [PMID:15173008] [10.1021/op500134e]
16. Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P et al.. (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation.. Nat Chem Biol, 2 (2): (95-102). [PMID:16415863] [10.1021/op500134e]
17. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C et al.. (2007) Patterns of somatic mutation in human cancer genomes.. Nature, 446 (7132): (153-8). [PMID:17344846] [10.1021/op500134e]
18. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM et al.. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.. J Med Chem, 47 (27): (6658-61). [PMID:15615512] [10.1021/op500134e]
19. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ et al.. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.. Cancer Res, 68 (22): (9280-90). [PMID:19010901] [10.1021/op500134e]
20. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J et al.. (2004) AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.. Cancer Res, 64 (14): (4931-41). [PMID:15256466] [10.1021/op500134e]
21. Nagasawa J, Mizokami A, Koshida K, Yoshida S, Naito K, Namiki M. (2006) Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.. Int J Urol, 13 (5): (587-92). [PMID:16771730] [10.1021/op500134e]
22. Solca FF, Baum A, Langkopf E, Dahmann G, Heider KH, Himmelsbach F, van Meel JC. (2004) Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives.. J Pharmacol Exp Ther, 311 (2): (502-9). [PMID:15199094] [10.1021/op500134e]
23. Barlaam B, Anderton J, Ballard P, Bradbury RH, Hennequin LF, Hickinson DM, Kettle JG, Kirk G, Klinowska T, Lambert-van der Brempt C et al.. (2013) Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.. ACS Med Chem Lett, 4 (8): (742-6). [PMID:24900741] [10.1021/op500134e]
24. Ballou LM, Selinger ES, Choi JY, Drueckhammer DG, Lin RZ. (2007) Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one.. J Biol Chem, 282 (33): (24463-70). [PMID:17562705] [10.1021/op500134e]
25. Klutchko SR, Zhou H, Winters RT, Tran TP, Bridges AJ, Althaus IW, Amato DM, Elliott WL, Ellis PA, Meade MA et al.. (2006) Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.. J Med Chem, 49 (4): (1475-85). [PMID:16480284] [10.1021/op500134e]
26. Zhang P, Hu HR, Huang ZH, Lei JY, Chu Y, Ye DY. (2012) Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.. Bioorg Med Chem Lett, 22 (23): (7232-6). [PMID:23099099] [10.1021/op500134e]
27. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ et al.. (2006) Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.. J Med Chem, 49 (12): (3563-80). [PMID:16759099] [10.1021/op500134e]
28. Aston NM, Bamborough P, Buckton JB, Edwards CD, Holmes DS, Jones KL, Patel VK, Smee PA, Somers DO, Vitulli G et al.. (2009) p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.. J Med Chem, 52 (20): (6257-69). [PMID:19772287] [10.1021/op500134e]
29. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H et al.. (2011) Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.. J Med Chem, 54 (20): (7066-83). [PMID:21936542] [10.1021/op500134e]
30. Nam HJ, Kim HP, Yoon YK, Hur HS, Song SH, Kim MS, Lee GS, Han SW, Im SA, Kim TY et al.. (2011) Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.. Cancer Lett, 302 (2): (155-65). [PMID:21306821] [10.1021/op500134e]
31. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA. (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.. Nat Chem Biol, 4 (11): (691-9). [PMID:18849971] [10.1021/op500134e]
32. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q et al.. (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).. Blood, 114 (14): (2984-92). [PMID:19654408] [10.1021/op500134e]
33. Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, Jansen M, Lin P, Payne A, Crosby RM et al.. (2005) Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.. Proc Natl Acad Sci USA, 102 (44): (16078-83). [PMID:16249345] [10.1021/op500134e]
34. Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA, Hunt JT, Rawlins DB, Shan W, Ahmed SZ et al.. (2004) N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent.. J Med Chem, 47 (7): (1719-28). [PMID:15027863] [10.1021/op500134e]
35. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F et al.. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.. Oncogene, 27 (34): (4702-11). [PMID:18408761] [10.1021/op500134e]
36. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C. (2009) Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).. J Med Chem, 52 (20): (6433-46). [PMID:19788238] [10.1021/op500134e]
37. Li X, Zuo Y, Tang G, Wang Y, Zhou Y, Wang X, Guo T, Xia M, Ding N, Pan Z. (2014) Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.. J Med Chem, 57 (12): (5112-28). [PMID:24915291] [10.1021/op500134e]
38. Burgess A, Wigan M, Giles N, Depinto W, Gillespie P, Stevens F, Gabrielli B. (2006) Inhibition of S/G2 phase CDK4 reduces mitotic fidelity.. J Biol Chem, 281 (15): (9987-95). [PMID:16476733] [10.1021/op500134e]
39. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM. (2009) Inhibitor hijacking of Akt activation.. Nat Chem Biol, 5 (7): (484-93). [PMID:19465931] [10.1021/op500134e]
40. Ott GR, Tripathy R, Cheng M, McHugh R, Anzalone AV, Underiner TL, Curry MA, Quail MR, Lu L, Wan W et al.. (2010) Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity.. ACS Med Chem Lett, 1 (9): (493-8). [PMID:24900237] [10.1021/op500134e]
41. Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C. (2010) Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.. J Med Chem, 53 (5): (2000-9). [PMID:20143778] [10.1021/op500134e]
42. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S et al.. (2012) Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.. Mol Cancer Ther, 11 (3): (582-93). [PMID:22248472] [10.1021/op500134e]
43. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR et al.. (2016) Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.. N Engl J Med, 374 (4): (323-32). [PMID:26641137] [10.1021/op500134e]
44. Kim KH, Maderna A, Schnute ME, Hegen M, Mohan S, Miyashiro J, Lin L, Li E, Keegan S, Lussier J et al.. (2011) Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.. Bioorg Med Chem Lett, 21 (21): (6258-63). [PMID:21958547] [10.1021/op500134e]
45. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al.. (2015) Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.. J Med Chem, 58 (23): (9154-70). [PMID:26509640] [10.1021/op500134e]
46. Telliez JB, Dowty ME, Wang L, Jussif J, Lin T, Li L, Moy E, Balbo P, Li W, Zhao Y et al.. (2016) Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.. ACS Chem Biol, 11 (12): (3442-3451). [PMID:27791347] [10.1021/op500134e]
47. Li X, Yang C, Wan H, Zhang G, Feng J, Zhang L, Chen X, Zhong D, Lou L, Tao W et al.. (2017) Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.. Eur J Pharm Sci, 110 (13): (51-61). [PMID:28115222] [10.1021/op500134e]
48. Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G et al.. (2017) Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.. Bioorg Med Chem, 25 (4): (1320-1328). [PMID:28038940] [10.1021/op500134e]
49. Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, Ding Y, Tamez V, Zhang Y, Mathur M et al.. (2015) Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.. J Med Chem, 58 (21): (8373-86). [PMID:26505898] [10.1021/op500134e]
50. Xie H, Lin L, Tong L, Jiang Y, Zheng M, Chen Z, Jiang X, Zhang X, Ren X, Qu W et al.. (2011) AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo.. PLoS ONE, 6 (7): (e21487). [PMID:21789172] [10.1021/op500134e]
51. Patel S, Harris SF, Gibbons P, Deshmukh G, Gustafson A, Kellar T, Lin H, Liu X, Liu Y, Liu Y et al.. (2015) Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12).. J Med Chem, 58 (20): (8182-99). [PMID:26431428] [10.1021/op500134e]
52. Heffron TP, Ndubaku CO, Salphati L, Alicke B, Cheong J, Drobnick J, Edgar K, Gould SE, Lee LB, Lesnick JD et al.. (2016) Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.. ACS Med Chem Lett, 7 (4): (351-6). [PMID:27096040] [10.1021/op500134e]
53. Qi B, Yang Y, Gong G, He H, Yue X, Xu X, Hu Y, Li J, Chen T, Wan X et al.. (2019) Discovery of N¹-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N³-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment.. Eur J Med Chem, 163 (13): (10-27). [PMID:30503936] [10.1021/op500134e]
54. Angst D, Gessier F, Janser P, Vulpetti A, Wälchli R, Beerli C, Littlewood-Evans A, Dawson J, Nuesslein-Hildesheim B, Wieczorek G et al.. (2020) Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.. J Med Chem, 63 (10): (5102-5118). [PMID:32083858] [10.1021/op500134e]
55. Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, Forero-Torres A, Peterson S. (2020) Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models.. Mol Cancer Ther, 19 (4): (976-987). [PMID:32241871] [10.1021/op500134e]
56. Czako B, Marszalek JR, Burke JP, Mandal P, Leonard PG, Cross JB, Mseeh F, Jiang Y, Chang EQ, Suzuki E et al.. (2020) Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.. J Med Chem, 71 (13): (1755-70). [PMID:32787110] [10.1021/acs.jmedchem.0c00936]
57. Yin L, Li H, Liu W, Yao Z, Cheng Z, Zhang H, Zou H. (2018) A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.. Eur J Med Chem, 144 (13): (1-28). [PMID:29247857] [10.1021/op500134e]
58. Pietilä M, Sahgal P, Peuhu E, Jäntti NZ, Paatero I, Närvä E, Al-Akhrass H, Lilja J, Georgiadou M, Andersen OM, Padzik A, Sihto H, Joensuu H, Blomqvist M, Saarinen I, Boström PJ, Taimen P, Ivaska J. () SORLA regulates endosomal trafficking and oncogenic fitness of HER2.. Nat Commun, [PMID:31138794] [http://pubmed.ncbi.nlm.nih.gov/31138794]
59. Qing-Shan Li,Xian-Hai Lv,Yan-Bin Zhang,Jing-Jun Dong,Wen-Ping Zhou,Yang Yang,Hai-Liang Zhu. (2012-10-03) Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamide moiety as potential anti-melanoma agents.. Bioorganic & medicinal chemistry letters, 22 ((21)): (6596-6601). [PMID:23025996]
60. Ajit Dhananjay Jagtap,Pei-Teh Chang,Jia-Rong Liu,Hsiao-Chun Wang,Nagendra B Kondekar,Li-Jiuan Shen,Hsiang-Wen Tseng,Grace Shiahuy Chen,Ji-Wang Chern. (2014-08-05) Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.. European journal of medicinal chemistry, 85 (268-288). [PMID:25089810]
61. Emily J Hanan,Charles Eigenbrot,Marian C Bryan,Daniel J Burdick,Bryan K Chan,Yuan Chen,Jennafer Dotson,Robert A Heald,Philip S Jackson,Hank La,Michael D Lainchbury,Shiva Malek,Hans E Purkey,Gabriele Schaefer,Stephen Schmidt,Eileen M Seward,Steve Sideris,Christine Tam,Shumei Wang,Siew Kuen Yeap,Ivana Yen,Jianping Yin,Christine Yu,Inna Zilberleyb,Timothy P Heffron. (2014-11-11) Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation.. Journal of medicinal chemistry, 57 ((23)): (10176-10191). [PMID:25383627]
62. Sandra N Milik,Amal Kamal Abdel-Aziz,Deena S Lasheen,Rabah A T Serya,Saverio Minucci,Khaled A M Abouzid. (2018-06-15) Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors.. European journal of medicinal chemistry, 155 (316-336). [PMID:29902719]
63. Xiaoqing Wu,Mingdong Li,Yang Qu,Wenhua Tang,Youguang Zheng,Jiqin Lian,Min Ji,Liang Xu. (2010-05-15) Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.. Bioorganic & medicinal chemistry, 18 ((11)): (3812-3822). [PMID:20466555]
64. Bing Yu,Li-da Tang,Yi-Liang Li,Shu-Hui Song,Xiao-Liang Ji,Mu-Sen Lin,Chun-Fu Wu. (2011-12-16) Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase.. Bioorganic & medicinal chemistry letters, 22 ((1)): (110-114). [PMID:22169262]
65. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G.. (2004) Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.. Bioorg Med Chem Lett, 14 (13): (3595-3599). [PMID:15177482] [10.1016/j.bmcl.2004.03.106]
66. Borzilleri RM, Zheng X, Qian L, Ellis C, Cai ZW, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Fura A, Kamath A, Vyas V, Tokarski JS, Barrish JC, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS.. (2005) Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.. J Med Chem, 48 (12): (3991-4008). [PMID:15943473] [10.1021/jm0501275]
67. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Neumann U, Rucklin G.. (2006) Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.. Bioorg Med Chem Lett, 16 (2): (262-266). [PMID:16249085] [10.1016/j.bmcl.2005.10.015]
68. Zhao H, Serby MD, Xin Z, Szczepankiewicz BG, Liu M, Kosogof C, Liu B, Nelson LT, Johnson EF, Wang S, Pederson T, Gum RJ, Clampit JE, Haasch DL, Abad-Zapatero C, Fry EH, Rondinone C, Trevillyan JM, Sham HL, Liu G.. (2006) Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors.. J Med Chem, 49 (15): (4455-4458). [PMID:16854050] [10.1021/jm060465l]
69. Borzilleri RM, Bhide RS, Barrish JC, D'Arienzo CJ, Derbin GM, Fargnoli J, Hunt JT, Jeyaseelan R, Kamath A, Kukral DW, Marathe P, Mortillo S, Qian L, Tokarski JS, Wautlet BS, Zheng X, Lombardo LJ.. (2006) Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.. J Med Chem, 49 (13): (3766-3769). [PMID:16789733] [10.1021/jm060347y]
70. Cheng ZY, Li WJ, He F, Zhou JM, Zhu XF.. (2007) Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase.. Bioorg Med Chem, 15 (3): (1533-1538). [PMID:17174554] [10.1016/j.bmc.2006.09.041]
71. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J.. (2007) Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.. Proc Natl Acad Sci U S A, 104 (50): (19936-19941). [PMID:18077425] [10.1073/pnas.0707498104]
72. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P.. (2008) Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.. J Med Chem, 51 (21): (6642-6645). [PMID:18834107] [10.1021/jm800986w]
73. Hubbard RD, Bamaung NY, Fidanze SD, Erickson SA, Palazzo F, Wilsbacher JL, Zhang Q, Tucker LA, Hu X, Kovar P, Osterling DJ, Johnson EF, Bouska J, Wang J, Davidsen SK, Bell RL, Sheppard GS.. (2009) Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases.. Bioorg Med Chem Lett, 19 (6): (1718-1721). [PMID:19217287] [10.1016/j.bmcl.2009.01.086]
74. Hur W, Velentza A, Kim S, Flatauer L, Jiang X, Valente D, Mason DE, Suzuki M, Larson B, Zhang J, Zagorska A, Didonato M, Nagle A, Warmuth M, Balk SP, Peters EC, Gray NS.. (2008) Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.. Bioorg Med Chem Lett, 18 (22): (5916-5919). [PMID:18667312] [10.1016/j.bmcl.2008.07.062]
75. Taldone T, Sun W, Chiosis G.. (2009) Discovery and development of heat shock protein 90 inhibitors.. Bioorg Med Chem, 17 (6): (2225-2235). [PMID:19017562] [10.1016/j.bmc.2008.10.087]
76. Li R, Pourpak A, Morris SW.. (2009) Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.. J Med Chem, 52 (16): (4981-5004). [PMID:19610618] [10.1021/jm9002395]
77. Cha MY, Lee KO, Kim JW, Lee CG, Song JY, Kim YH, Lee GS, Park SB, Kim MS.. (2009) Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.. J Med Chem, 52 (21): (6880-6888). [PMID:19888761] [10.1021/jm901146p]
78. Li J, Kaoud TS, Laroche C, Dalby KN, Kerwin SM.. (2009) Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles.. Bioorg Med Chem Lett, 19 (22): (6293-6297). [PMID:19822424] [10.1016/j.bmcl.2009.09.094]
79. Shomin CD, Meyer SC, Ghosh I.. (2009) Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling.. Bioorg Med Chem, 17 (17): (6196-6202). [PMID:19674907] [10.1016/j.bmc.2009.07.056]
80. Wee XK, Yeo WK, Zhang B, Tan VB, Lim KM, Tay TE, Go ML.. (2009) Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.. Bioorg Med Chem, 17 (21): (7562-7571). [PMID:19783149] [10.1016/j.bmc.2009.09.008]
81. Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD.. (2009) Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors.. Bioorg Med Chem Lett, 19 (21): (6122-6126). [PMID:19783434] [10.1016/j.bmcl.2009.09.010]
82. Deng X, Lim SM, Zhang J, Gray NS.. (2010) Broad spectrum alkynyl inhibitors of T315I Bcr-Abl.. Bioorg Med Chem Lett, 20 (14): (4196-4200). [PMID:20541934] [10.1016/j.bmcl.2010.05.043]
83. Mahboobi S, Sellmer A, Winkler M, Eichhorn E, Pongratz H, Ciossek T, Baer T, Maier T, Beckers T.. (2010) Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.. J Med Chem, 53 (24): (8546-8555). [PMID:21080629] [10.1021/jm100665z]
84. Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Yano J, Aertgeerts K, Kamiyama K.. (2011) Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.. J Med Chem, 54 (23): (8030-8050). [PMID:22003817] [10.1021/jm2008634]
85. Suzuki N, Shiota T, Watanabe F, Haga N, Murashi T, Ohara T, Matsuo K, Omori N, Yari H, Dohi K, Inoue M, Iguchi M, Sentou J, Wada T.. (2012) Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases.. Bioorg Med Chem Lett, 22 (1): (456-460). [PMID:22101132] [10.1016/j.bmcl.2011.10.103]
86. Caruso M, Valsasina B, Ballinari D, Bertrand J, Brasca MG, Caldarelli M, Cappella P, Fiorentini F, Gianellini LM, Scolaro A, Beria I.. (2012) 5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors.. Bioorg Med Chem Lett, 22 (1): (96-101). [PMID:22154349] [10.1016/j.bmcl.2011.11.065]
87. Bijian K, Zhang Z, Xu B, Jie S, Chen B, Wan S, Wu J, Jiang T, Alaoui-Jamali MA.. (2012) Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.. Eur J Med Chem, 48 (143-152). [PMID:22204902] [10.1016/j.ejmech.2011.12.006]
88. Cuny GD, Ulyanova NP, Patnaik D, Liu JF, Lin X, Auerbach K, Ray SS, Xian J, Glicksman MA, Stein RL, Higgins JM.. (2012) Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.. Bioorg Med Chem Lett, 22 (5): (2015-2019). [PMID:22335895] [10.1016/j.bmcl.2012.01.028]
89. Cha MY, Lee KO, Kang SJ, Jung YH, Song JY, Choi KJ, Byun JY, Lee HJ, Lee GS, Park SB, Kim MS.. (2012) Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.. J Med Chem, 55 (6): (2846-2857). [PMID:22372864] [10.1021/jm201758g]
90. Turrado C, Puig T, García-Cárceles J, Artola M, Benhamú B, Ortega-Gutiérrez S, Relat J, Oliveras G, Blancafort A, Haro D, Marrero PF, Colomer R, López-Rodríguez ML.. (2012) New synthetic inhibitors of fatty acid synthase with anticancer activity.. J Med Chem, 55 (11): (5013-5023). [PMID:22559865] [10.1021/jm2016045]
91. Tell V, Holzer M, Herrmann L, Mahmoud KA, Schächtele C, Totzke F, Hilgeroth A.. (2012) Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases.. Bioorg Med Chem Lett, 22 (22): (6914-6918). [PMID:23039927] [10.1016/j.bmcl.2012.09.006]
92. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, Gray NS.. (2012) GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.. Bioorg Med Chem Lett, 22 (17): (5625-5629). [PMID:22863203] [10.1016/j.bmcl.2012.06.104]
93. Zhang P, Hu HR, Bian SH, Huang ZH, Chu Y, Ye DY.. (2013) Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).. Eur J Med Chem, 61 (95-103). [PMID:23047001] [10.1016/j.ejmech.2012.09.021]
94. Yang LL, Li GB, Ma S, Zou C, Zhou S, Sun QZ, Cheng C, Chen X, Wang LJ, Feng S, Li LL, Yang SY.. (2013) Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.. J Med Chem, 56 (4): (1641-1655). [PMID:23362959] [10.1021/jm301537p]
95. Brown A, Shi Q, Moore TW, Yoon Y, Prussia A, Maddox C, Liotta DC, Shim H, Snyder JP.. (2013) Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.. J Med Chem, 56 (9): (3456-3466). [PMID:23550937] [10.1021/jm4002692]
96. Mortensen DS, Sapienza J, Lee BG, Perrin-Ninkovic SM, Harris R, Shevlin G, Parnes JS, Whitefield B, Hickman M, Khambatta G, Bisonette RR, Peng S, Gamez JC, Leisten J, Narla RK, Fultz KE, Sankar S.. (2013) Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.. Bioorg Med Chem Lett, 23 (6): (1588-1591). [PMID:23414803] [10.1016/j.bmcl.2013.01.110]
97. Lin WH, Hsu JT, Hsieh SY, Chen CT, Song JS, Yen SC, Hsu T, Lu CT, Chen CH, Chou LH, Yang YN, Chiu CH, Chen CP, Tseng YJ, Yen KJ, Yeh CF, Chao YS, Yeh TK, Jiaang WT.. (2013) Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).. Bioorg Med Chem, 21 (11): (2856-2867). [PMID:23618709] [10.1016/j.bmc.2013.03.083]
98. Pauwels D, Klaassen H, Lahortiga I, Kilonda A, Jacobs K, Sweron B, Corbau R, Chaltin P, Marchand A, Cools J.. (2013) Identification of novel FLT3 kinase inhibitors.. Eur J Med Chem, 63 (713-721). [PMID:23567961] [10.1016/j.ejmech.2013.03.024]
99. Bowers S, Truong AP, Ye M, Aubele DL, Sealy JM, Neitz RJ, Hom RK, Chan W, Dappen MS, Galemmo RA, Konradi AW, Sham HL, Zhu YL, Beroza P, Tonn G, Zhang H, Hoffman J, Motter R, Fauss D, Tanaka P, Bova MP, Ren Z, Tam D, Ruslim L, Baker J, Pandya D, Diep L, Fitzgerald K, Artis DR, Anderson JP, Bergeron M.. (2013) Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.. Bioorg Med Chem Lett, 23 (9): (2743-2749). [PMID:23522834] [10.1016/j.bmcl.2013.02.065]
100. Banappagari S, McCall A, Fontenot K, Vicente MG, Gujar A, Satyanarayanajois S.. (2013) Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain.. Eur J Med Chem, 65 (60-69). [PMID:23688700] [10.1016/j.ejmech.2013.04.038]
101. Zhou W, Liu X, Tu Z, Zhang L, Ku X, Bai F, Zhao Z, Xu Y, Ding K, Ding K, Li H.. (2013) Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.. J Med Chem, 56 (20): (7821-7837). [PMID:24053674] [10.1021/jm401045n]
102. Nesi G, Sestito S, Mey V, Ricciardi S, Falasca M, Danesi R, Lapucci A, Breschi MC, Fogli S, Rapposelli S.. (2013) Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer.. ACS Med Chem Lett, 4 (12): (1137-1141). [PMID:24900620] [10.1021/ml400162g]
103. Cheng X, Merz KH, Vatter S, Christ J, Wölfl S, Eisenbrand G.. (2014) 7,7'-Diazaindirubin--a small molecule inhibitor of casein kinase 2 in vitro and in cells.. Bioorg Med Chem, 22 (1): (247-255). [PMID:24326279] [10.1016/j.bmc.2013.11.031]
104. Sridhar J, Sfondouris ME, Bratton MR, Nguyen TL, Townley I, Klein Stevens CL, Jones FE.. (2014) Identification of quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer.. Bioorg Med Chem Lett, 24 (1): (126-131). [PMID:24355130] [10.1016/j.bmcl.2013.11.064]
105. Cheng H, Chang Y, Zhang L, Luo J, Tu Z, Lu X, Zhang Q, Lu J, Ren X, Ding K, Ding K.. (2014) Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib.. J Med Chem, 57 (6): (2692-2703). [PMID:24588073] [10.1021/jm500007h]
106. Szokol B, Gyulavári P, Kurkó I, Baska F, Szántai-Kis C, Greff Z, Orfi Z, Peták I, Pénzes K, Torka R, Ullrich A, Orfi L, Vántus T, Kéri G.. (2014) Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.. ACS Med Chem Lett, 5 (4): (298-303). [PMID:24900830] [10.1021/ml4003309]
107. Blake JF, Gaudino JJ, De Meese J, Mohr P, Chicarelli M, Tian H, Garrey R, Thomas A, Siedem CS, Welch MB, Kolakowski G, Kaus R, Burkard M, Martinson M, Chen H, Dean B, Dudley DA, Gould SE, Pacheco P, Shahidi-Latham S, Wang W, West K, Yin J, Moffat J, Schwarz JB.. (2014) Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.. Bioorg Med Chem Lett, 24 (12): (2635-2639). [PMID:24813737] [10.1016/j.bmcl.2014.04.068]
108. Sangani CB, Makawana JA, Duan YT, Yin Y, Teraiya SB, Thumar NJ, Zhu HL.. (2014) Design, synthesis and molecular modeling of biquinoline-pyridine hybrids as a new class of potential EGFR and HER-2 kinase inhibitors.. Bioorg Med Chem Lett, 24 (18): (4472-4476). [PMID:25172421] [10.1016/j.bmcl.2014.07.094]
109. Horbert R, Pinchuk B, Johannes E, Schlosser J, Schmidt D, Cappel D, Totzke F, Schächtele C, Peifer C.. (2015) Optimization of potent DFG-in inhibitors of platelet derived growth factor receptorβ (PDGF-Rβ) guided by water thermodynamics.. J Med Chem, 58 (1): (170-182). [PMID:25007344] [10.1021/jm500373x]
110. Lawrence HR, Mahajan K, Luo Y, Zhang D, Tindall N, Huseyin M, Gevariya H, Kazi S, Ozcan S, Mahajan NP, Lawrence NJ.. (2015) Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.. J Med Chem, 58 (6): (2746-2763). [PMID:25699576] [10.1021/jm501929n]
111. Chen CT, Hsu JT, Lin WH, Lu CT, Yen SC, Hsu T, Huang YL, Song JS, Chen CH, Chou LH, Yen KJ, Chen CP, Kuo PC, Huang CL, Liu HE, Chao YS, Yeh TK, Jiaang WT.. (2015) Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.. Eur J Med Chem, 100 (151-161). [PMID:26081023] [10.1016/j.ejmech.2015.05.008]
112. Lin XD, Yang HW, Ma S, Li WW, Zhang CH, Wang WJ, Xiang R, Li LL, Yang SY.. (2015) Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors.. Bioorg Med Chem Lett, 25 (20): (4534-4538). [PMID:26342867] [10.1016/j.bmcl.2015.08.068]
113. Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L.. (2015) Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.. Bioorg Med Chem, 23 (21): (7000-7006). [PMID:26455654] [10.1016/j.bmc.2015.09.038]
114. Elkamhawy A, Farag AK, Viswanath AN, Bedair TM, Leem DG, Lee KT, Pae AN, Roh EJ.. (2015) Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.. Bioorg Med Chem Lett, 25 (22): (5147-5154). [PMID:26475520] [10.1016/j.bmcl.2015.10.003]
115. Qin M, Wang T, Xu B, Ma Z, Jiang N, Xie H, Gong P, Zhao Y.. (2015) Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.. Eur J Med Chem, 104 (115-126). [PMID:26451770] [10.1016/j.ejmech.2015.09.031]
116. Simon-Szabó L, Kokas M, Greff Z, Boros S, Bánhegyi P, Zsákai L, Szántai-Kis C, Vantus T, Mandl J, Bánhegyi G, Vályi-Nagy I, Őrfi L, Ullrich A, Csala M, Kéri G.. (2016) Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes.. Bioorg Med Chem Lett, 26 (2): (424-428). [PMID:26704265] [10.1016/j.bmcl.2015.11.099]
117. Schiemann K, Mallinger A, Wienke D, Esdar C, Poeschke O, Busch M, Rohdich F, Eccles SA, Schneider R, Raynaud FI, Czodrowski P, Musil D, Schwarz D, Urbahns K, Blagg J.. (2016) Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.. Bioorg Med Chem Lett, 26 (5): (1443-1451). [PMID:26852363] [10.1016/j.bmcl.2016.01.062]
118. Jung ME, Byun BJ, Kim HM, Lee JY, Park JH, Lee N, Son YH, Choi SU, Yang KM, Kim SJ, Lee K, Kim YC, Choi G.. (2016) Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening.. Bioorg Med Chem Lett, 26 (11): (2719-2723). [PMID:27106709] [10.1016/j.bmcl.2016.03.111]
119. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A.. (2016) Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.. J Med Chem, 59 (8): (3886-3905). [PMID:27010810] [10.1021/acs.jmedchem.6b00087]
120. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J.. (2016) Identification of quinones as novel PIM1 kinase inhibitors.. Bioorg Med Chem Lett, 26 (13): (3187-3191). [PMID:27173800] [10.1016/j.bmcl.2016.04.079]
121. Tantak MP, Gupta V, Nikhil K, Arun V, Singh RP, Jha PN, Shah K, Kumar D.. (2016) Sequential one-pot synthesis of bis(indolyl)glyoxylamides: Evaluation of antibacterial and anticancer activities.. Bioorg Med Chem Lett, 26 (13): (3167-3171). [PMID:27173802] [10.1016/j.bmcl.2016.04.080]
122. Yin S, Tang C, Wang B, Zhang Y, Zhou L, Xue L, Zhang C.. (2016) Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold.. Eur J Med Chem, 120 (26-36). [PMID:27187856] [10.1016/j.ejmech.2016.04.072]
123. Kim H, Lee C, Yang JS, Choi S, Park CH, Kang JS, Oh SJ, Yun J, Kim MH, Han G.. (2016) Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia.. Eur J Med Chem, 120 (74-85). [PMID:27187860] [10.1016/j.ejmech.2016.05.022]
124. Pallerla S, Gauthier T, Sable R, Jois SD.. (2017) Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells.. Eur J Med Chem, 125 (914-924). [PMID:27769032] [10.1016/j.ejmech.2016.10.015]
125. Chen Y, Zheng Y, Jiang Q, Qin F, Zhang Y, Fu L, He G.. (2017) Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells.. Eur J Med Chem, 127 (997-1011). [PMID:27839788] [10.1016/j.ejmech.2016.11.009]
126. Argyros O, Lougiakis N, Kouvari E, Papafotika A, Raptopoulou CP, Psycharis V, Christoforidis S, Pouli N, Marakos P, Tamvakopoulos C.. (2017) Design and synthesis of novel 7-aminosubstituted pyrido[2,3-b]pyrazines exhibiting anti-breast cancer activity.. Eur J Med Chem, 126 (954-968). [PMID:28006668] [10.1016/j.ejmech.2016.12.025]
127. Shi Y, Park J, Lagisetti C, Zhou W, Sambucetti LC, Webb TR.. (2017) A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.. Bioorg Med Chem Lett, 27 (3): (406-412). [PMID:28049589] [10.1016/j.bmcl.2016.12.056]
128. Hamed MM, Darwish SS, Herrmann J, Abadi AH, Engel M.. (2017) First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.. J Med Chem, 60 (7): (2853-2868). [PMID:28291344] [10.1021/acs.jmedchem.6b01774]
129. Zhu W, Chen H, Wang Y, Wang J, Peng X, Chen X, Gao Y, Li C, He Y, Ai J, Geng M, Zheng M, Liu H.. (2017) Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.. J Med Chem, 60 (14): (6018-6035). [PMID:28714692] [10.1021/acs.jmedchem.7b00076]
130. Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy R, Coraggio M, Dong L, Eigenbrot C, Erickson R, Ghilardi N, Hau J, Katewa A, Kohli PB, Lee W, Lubach JW, McKenzie BS, Ortwine DF, Schutt L, Tay S, Wei B, Reif K, Liu L, Wong H, Young WB.. (2018) Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.. J Med Chem, 61 (6): (2227-2245). [PMID:29457982] [10.1021/acs.jmedchem.7b01712]
131. Wang A, Li X, Wu H, Zou F, Yan XE, Chen C, Hu C, Yu K, Wang W, Zhao P, Wu J, Qi Z, Wang W, Wang B, Wang L, Ren T, Zhang S, Yun CH, Liu J, Liu Q.. (2017) Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.. J Med Chem, 60 (7): (2944-2962). [PMID:28282122] [10.1021/acs.jmedchem.6b01907]
132. Juchum M, Günther M, Döring E, Sievers-Engler A, Lämmerhofer M, Laufer S.. (2017) Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.. J Med Chem, 60 (11): (4636-4656). [PMID:28482151] [10.1021/acs.jmedchem.7b00178]
133. Zhang H, Wu W, Feng C, Liu Z, Bai E, Wang X, Lei M, Cheng H, Feng H, Shi J, Wang J, Zhang Z, Jin T, Chen S, Hu S, Zhu Y.. (2017) Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants.. Eur J Med Chem, 135 (12-23). [PMID:28426996] [10.1016/j.ejmech.2017.04.036]
134. He L, Li D, Zhang C, Bai P, Chen L.. (2017) Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC.. Bioorg Med Chem Lett, 27 (17): (4171-4175). [PMID:28734581] [10.1016/j.bmcl.2017.07.009]
135. Patel S, Meilandt WJ, Erickson RI, Chen J, Deshmukh G, Estrada AA, Fuji RN, Gibbons P, Gustafson A, Harris SF, Imperio J, Liu W, Liu X, Liu Y, Lyssikatos JP, Ma C, Yin J, Lewcock JW, Siu M.. (2017) Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease.. J Med Chem, 60 (19): (8083-8102). [PMID:28929759] [10.1021/acs.jmedchem.7b00843]
136. Malki WH, Gouda AM, Ali HEA, Al-Rousan R, Samaha D, Abdalla AN, Bustamante J, Abd Elmageed ZY, Ali HI.. (2018) Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition.. Eur J Med Chem, 152 (31-52). [PMID:29684708] [10.1016/j.ejmech.2018.04.029]
137. Reiersølmoen AC, Han J, Sundby E, Hoff BH.. (2018) Identification of fused pyrimidines as interleukin 17 secretion inhibitors.. Eur J Med Chem, 155 (562-578). [PMID:29909341] [10.1016/j.ejmech.2018.06.019]
138. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.. (2018) Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.. Bioorg Med Chem, 26 (3): (590-602). [PMID:29289448] [10.1016/j.bmc.2017.12.020]
139. Assadieskandar A, Yu C, Maisonneuve P, Liu X, Chen YC, Prakash GKS, Kurinov I, Sicheri F, Zhang C.. (2018) Effects of rigidity on the selectivity of protein kinase inhibitors.. Eur J Med Chem, 146 (519-528). [PMID:29407977] [10.1016/j.ejmech.2018.01.053]
140. Wang Q, Liu F, Qi S, Qi Z, Yan XE, Wang B, Wang A, Wang W, Chen C, Liu X, Jiang Z, Hu Z, Wang L, Wang W, Ren T, Zhang S, Yun CH, Liu Q, Liu J.. (2018) Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.. Eur J Med Chem, 150 (366-384). [PMID:29544149] [10.1016/j.ejmech.2018.03.003]
141. La Pietra V, Sartini S, Botta L, Antonelli A, Ferrari SM, Fallahi P, Moriconi A, Coviello V, Quattrini L, Ke YY, Hsing-Pang H, Da Settimo F, Novellino E, La Motta C, Marinelli L.. (2018) Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.. Eur J Med Chem, 150 (491-505). [PMID:29549836] [10.1016/j.ejmech.2018.02.080]
142. He LJ, Yang DL, Li SQ, Zhang YJ, Tang Y, Lei J, Frett B, Lin HK, Li HY, Chen ZZ, Xu ZG.. (2018) Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells.. Bioorg Med Chem, 26 (14): (3899-3908). [PMID:29921474] [10.1016/j.bmc.2018.06.010]
143. Hossam M, Lasheen DS, Ismail NSM, Esmat A, Mansour AM, Singab ANB, Abouzid KAM.. (2018) Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.. Eur J Med Chem, 144 (330-348). [PMID:29275232] [10.1016/j.ejmech.2017.12.022]
144. Pan Z, Chen Y, Liu J, Jiang Q, Yang S, Guo L, He G.. (2018) Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.. Eur J Med Chem, 144 (517-528). [PMID:29288948] [10.1016/j.ejmech.2017.12.046]
145. Liu H, Liang H, Meng H, Deng X, Zhang X, Lai L.. (2018) A novel allosteric inhibitor that prevents IKKβ activation.. Medchemcomm, 9 (2): (239-243). [PMID:30108917] [10.1039/C7MD00599G]
146. Naik H, Gauthier T, Singh S, Jois S.. (2018) Design of novel lipidated peptidomimetic conjugates for targeting EGFR heterodimerization in HER2 + cancer.. Bioorg Med Chem Lett, 28 (22): (3506-3513). [PMID:30314880] [10.1016/j.bmcl.2018.10.005]
147. Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.. (2018) Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.. Bioorg Med Chem Lett, 28 (20): (3356-3362). [PMID:30227946] [10.1016/j.bmcl.2018.09.006]
148. Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, Huang T, Ge J, Wang L, Ren T, Wang Y, Liu J, Liu Q.. (2018) Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.. Eur J Med Chem, 158 (896-916). [PMID:30253346] [10.1016/j.ejmech.2018.09.025]
149. Zhang Y, Lv H, Luo L, Xu Y, Pan Y, Wang Y, Lin H, Xiong J, Guo P, Zhang J, Li X, Ye F.. (2018) Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.. Eur J Med Chem, 157 (1300-1325). [PMID:30195240] [10.1016/j.ejmech.2018.08.031]
150. Milik SN, Lasheen DS, Serya RAT, Abouzid KAM.. (2017) How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.. Eur J Med Chem, 142 (131-151). [PMID:28754471] [10.1016/j.ejmech.2017.07.023]
151. Dodo K, Kuboki E, Shimizu T, Imamura R, Magarisawa M, Takahashi M, Tokuhiro T, Yotsumoto S, Asano K, Nakao S, Terayama N, Suda T, Tanaka M, Sodeoka M.. (2019) Development of a Water-Soluble Indolylmaleimide Derivative IM-93 Showing Dual Inhibition of Ferroptosis and NETosis.. ACS Med Chem Lett, 10 (9): (1272-1278). [PMID:31531196] [10.1021/acsmedchemlett.9b00142]
152. Zhang Q, Hu X, Wan G, Wang J, Li L, Wu X, Liu Z, Yu L.. (2019) Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer.. Eur J Med Chem, 184 (111728-111728). [PMID:31610375] [10.1016/j.ejmech.2019.111728]
153. Narayan S, Ramisetti S, Jaiswal AS, Law BK, Singh-Pillay A, Singh P, Amin S, Sharma AK.. (2019) ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.. Eur J Med Chem, 161 (456-467). [PMID:30384048] [10.1016/j.ejmech.2018.10.052]
154. Ju Y, Wu J, Yuan X, Zhao L, Zhang G, Li C, Qiao R.. (2018) Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.. J Med Chem, 61 (24): (11372-11383). [PMID:30508379] [10.1021/acs.jmedchem.8b01612]
155. Das D, Xie L, Wang J, Xu X, Zhang Z, Shi J, Le X, Hong J.. (2019) Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities - Part 1.. Bioorg Med Chem Lett, 29 (4): (591-596). [PMID:30600209] [10.1016/j.bmcl.2018.12.056]
156. Wang Y, Dou X, Jiang L, Jin H, Zhang L, Zhang L, Liu Z.. (2019) Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.. Eur J Med Chem, 171 (221-234). [PMID:30925338] [10.1016/j.ejmech.2019.03.039]
157. Zhang C, Pei H, He J, Zhu J, Li W, Niu T, Xiang M, Chen L.. (2019) Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.. Eur J Med Chem, 169 (121-143). [PMID:30875504] [10.1016/j.ejmech.2019.02.077]
158. Liang X, Zang J, Li X, Tang S, Huang M, Geng M, Chou CJ, Li C, Cao Y, Xu W, Liu H, Zhang Y.. (2019) Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.. J Med Chem, 62 (8): (3898-3923). [PMID:30901208] [10.1021/acs.jmedchem.8b01597]
159. Harris PA, Faucher N, George N, Eidam PM, King BW, White GV, Anderson NA, Bandyopadhyay D, Beal AM, Beneton V, Berger SB, Campobasso N, Campos S, Capriotti CA, Cox JA, Daugan A, Donche F, Fouchet MH, Finger JN, Geddes B, Gough PJ, Grondin P, Hoffman BL, Hoffman SJ, Hutchinson SE, Jeong JU, Jigorel E, Lamoureux P, Leister LK, Lich JD, Mahajan MK, Meslamani J, Mosley JE, Nagilla R, Nassau PM, Ng SL, Ouellette MT, Pasikanti KK, Potvain F, Reilly MA, Rivera EJ, Sautet S, Schaeffer MC, Sehon CA, Sun H, Thorpe JH, Totoritis RD, Ward P, Wellaway N, Wisnoski DD, Woolven JM, Bertin J, Marquis RW.. (2019) Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.. J Med Chem, 62 (10): (5096-5110). [PMID:31013427] [10.1021/acs.jmedchem.9b00318]
160. Gavriil ES, Doukatas A, Karampelas T, Myrianthopoulos V, Dimitrakis S, Mikros E, Marakos P, Tamvakopoulos C, Pouli N.. (2019) Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy.. Eur J Med Chem, 176 (393-409). [PMID:31125894] [10.1016/j.ejmech.2019.05.029]
161. Szabadkai I, Torka R, Garamvölgyi R, Baska F, Gyulavári P, Boros S, Illyés E, Choidas A, Ullrich A, Őrfi L.. (2018) Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors.. J Med Chem, 61 (14): (6277-6292). [PMID:29928803] [10.1021/acs.jmedchem.8b00672]
162. Wang X, Yu C, Wang C, Ma Y, Wang T, Li Y, Huang Z, Zhou M, Sun P, Zheng J, Yang S, Fan Y, Xiang R.. (2019) Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.. Eur J Med Chem, 181 (111535-111535). [PMID:31376566] [10.1016/j.ejmech.2019.07.038]
163. Zhao L, Li Y, Wang Y, Qiao Z, Miao Z, Yang J, Huang L, Tian C, Li L, Chen D, Yang S.. (2019) Discovery of 4H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models.. J Med Chem, 62 (23): (10691-10710). [PMID:31693351] [10.1021/acs.jmedchem.9b01143]
164. Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS.. (2017) Discovery of a potent dual ALK and EGFR T790M inhibitor.. Eur J Med Chem, 136 (497-510). [PMID:28528303] [10.1016/j.ejmech.2017.04.079]
165. Wang Y, Li L, Fan J, Dai Y, Jiang A, Geng M, Ai J, Duan W.. (2018) Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors.. J Med Chem, 61 (20): (9085-9104). [PMID:29522671] [10.1021/acs.jmedchem.7b01843]
166. Bronner SM, Merrick KA, Murray J, Salphati L, Moffat JG, Pang J, Sneeringer CJ, Dompe N, Cyr P, Purkey H, Boenig GL, Li J, Kolesnikov A, Larouche-Gauthier R, Lai KW, Shen X, Aubert-Nicol S, Chen YC, Cheong J, Crawford JJ, Hafner M, Haghshenas P, Jakalian A, Leclerc JP, Lim NK, O'Brien T, Plise EG, Shalan H, Sturino C, Wai J, Xiao Y, Yin J, Zhao L, Gould S, Olivero A, Heffron TP.. (2019) Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.. Bioorg Med Chem Lett, 29 (16): (2294-2301). [PMID:31307887] [10.1016/j.bmcl.2019.06.021]
167. Oukoloff K, Coquelle N, Bartolini M, Naldi M, Le Guevel R, Bach S, Josselin B, Ruchaud S, Catto M, Pisani L, Denora N, Iacobazzi RM, Silman I, Sussman JL, Buron F, Colletier JP, Jean L, Routier S, Renard PY.. (2019) Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3.. Eur J Med Chem, 168 (58-77). [PMID:30798053] [10.1016/j.ejmech.2018.12.063]
168. Saha T, Makar S, Swetha R, Gutti G, Singh SK.. (2019) Estrogen signaling: An emanating therapeutic target for breast cancer treatment.. Eur J Med Chem, 177 (116-143). [PMID:31129450] [10.1016/j.ejmech.2019.05.023]
169. Sever B, Altıntop MD, Radwan MO, Özdemir A, Otsuka M, Fujita M, Ciftci HI.. (2019) Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.. Eur J Med Chem, 182 (111648-111648). [PMID:31493743] [10.1016/j.ejmech.2019.111648]
170. Wang Q, Dai Y, Ji Y, Shi H, Guo Z, Chen D, Chen Y, Peng X, Gao Y, Wang X, Chen L, Jiang Y, Geng M, Shen J, Ai J, Xiong B.. (2019) Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.. Eur J Med Chem, 163 (671-689). [PMID:30572178] [10.1016/j.ejmech.2018.12.015]
171. Xi M, Chen T, Wu C, Gao X, Wu Y, Luo X, Du K, Yu L, Cai T, Shen R, Sun H.. (2019) CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors.. Eur J Med Chem, 164 (77-91). [PMID:30594029] [10.1016/j.ejmech.2018.11.076]
172. Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, Zhang B, Wei M, Liu J, Luo L, Tang Z, Song H, Guo Y, Liu X, Su D, Zhang S, Song X, Zhou X, Hong Y, Chen S, Cheng Z, Young S, Wei Q, Wang H, Wang Q, Lv L, Wang F, Xu H, Sun H, Xing H, Li N, Zhang W, Wang Z, Liu G, Sun Z, Zhou D, Li W, Liu L, Wang L, Wang Z.. (2019) Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.. J Med Chem, 62 (17): (7923-7940). [PMID:31381333] [10.1021/acs.jmedchem.9b00687]
173. Lin SY, Chang Hsu Y, Peng YH, Ke YY, Lin WH, Sun HY, Shiao HY, Kuo FM, Chen PY, Lien TW, Chen CH, Chu CY, Wang SY, Yeh KC, Chen CP, Hsu TA, Wu SY, Yeh TK, Chen CT, Hsieh HP.. (2019) Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.. J Med Chem, 62 (22): (10108-10123). [PMID:31560541] [10.1021/acs.jmedchem.9b00722]
174. Mansour TS, Pallepati RR, Basetti V.. (2020) Potent dual EGFR/Her4 tyrosine kinase inhibitors containing novel (1,2-dithiolan-4-yl)acetamides.. Bioorg Med Chem Lett, 30 (16): (127288-127288). [PMID:32631510] [10.1016/j.bmcl.2020.127288]
175. Zak M,Hanan EJ,Lupardus P,Brown DG,Robinson C,Siu M,Lyssikatos JP,Romero FA,Zhao G,Kellar T,Mendonca R,Ray NC,Goodacre SC,Crackett PH,McLean N,Hurley CA,Yuen PW,Cheng YX,Liu X,Liimatta M,Kohli PB,Nonomiya J,Salmon G,Buckley G,Lloyd J,Gibbons P,Ghilardi N,Kenny JR,Johnson A. (2019) Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.. Bioorg Med Chem Lett, 29 (12.0): (1522-1531). [PMID:30981576] [10.1016/j.bmcl.2019.04.008]
176. Hamilton GL,Chen H,Deshmukh G,Eigenbrot C,Fong R,Johnson A,Kohli PB,Lupardus PJ,Liederer BM,Ramaswamy S,Wang H,Wang J,Xu Z,Zhu Y,Vucic D,Patel S. (2019) Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group.. Bioorg Med Chem Lett, 29 (12.0): (1497-1501). [PMID:31000154] [10.1016/j.bmcl.2019.04.014]
177. Pulz R,Angst D,Dawson J,Gessier F,Gutmann S,Hersperger R,Hinniger A,Janser P,Koch G,Revesz L,Vulpetti A,Waelchli R,Zimmerlin A,Cenni B. (2019) Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.. ACS Med Chem Lett, 10 (10.0): (1467-1472). [PMID:31620235] [10.1021/acsmedchemlett.9b00317]
178. Lategahn J,Hardick J,Grabe T,Niggenaber J,Jeyakumar K,Keul M,Tumbrink HL,Becker C,Hodson L,Kirschner T,Klövekorn P,Ketzer J,Baumann M,Terheyden S,Unger A,Weisner J,Müller MP,van Otterlo WAL,Bauer S,Rauh D. (2020) Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.. J Med Chem, 63 (20.0): (11725-11755). [PMID:32931277] [10.1021/acs.jmedchem.0c00870]
179. Baillache, Daniel J., Unciti-Broceta, Asier. (2020) Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold. RSC Med Chem, 11 (10): (1112-1135). [PMID:33479617] [10.1039/d0md00227e]
180. May-Dracka TL,Arduini R,Bertolotti-Ciarlet A,Bhisetti G,Brickelmaier M,Cahir-McFarland E,Enyedy I,Fontenot JD,Hesson T,Little K,Lyssikatos J,Marcotte D,McKee T,Murugan P,Patterson T,Peng H,Rushe M,Silvian L,Spilker K,Wu P,Xin Z,Burkly LC. (2018) Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity.. Bioorg Med Chem Lett, 28 (10): (1964-1971). [PMID:29636220] [10.1016/j.bmcl.2018.03.032]
181. Shu L,Chen C,Huan X,Huang H,Wang M,Zhang J,Yan Y,Liu J,Zhang T,Zhang D. (2020) Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors.. Eur J Med Chem, 191 (112148-112148). [PMID:32097841] [10.1016/j.ejmech.2020.112148]
182. Mahajan D,Sen S,Kuila B,Sharma A,Arora R,Sagar M,Mahapatra AR,Gawade LB,Dugar S. (2020) Discovery and Development of SPR519 as a Potent, Selective, and Orally Bioavailable Inhibitor of PI3Kα and mTOR Kinases for the Treatment of Solid Tumors.. J Med Chem, 63 (19): (11121-11130). [PMID:32897703] [10.1021/acs.jmedchem.0c01061]
183. Elseginy SA,Hamdy R,Menon V,Almehdi AM,El-Awady R,Soliman SSM. (2020) Design, synthesis, and computational validation of novel compounds selectively targeting HER2-expressing breast cancer.. Bioorg Med Chem Lett, 30 (24): (127658-127658). [PMID:33130288] [10.1016/j.bmcl.2020.127658]
184. Michellys PY,Chen B,Jiang T,Jin Y,Lu W,Marsilje TH,Pei W,Uno T,Zhu X,Wu B,Nguyen TN,Bursulaya B,Lee C,Li N,Kim S,Tuntland T,Liu B,Sun F,Steffy A,Hood T. (2016) Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors.. Bioorg Med Chem Lett, 26 (3.0): (1090-1096). [PMID:26750252] [10.1016/j.bmcl.2015.11.049]
185. Ebrahim HY,Mohyeldin MM,Hailat MM,El Sayed KA. (2016) (1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies.. Bioorg Med Chem, 24 (22.0): (5748-5761). [PMID:27681240] [10.1016/j.bmc.2016.09.032]
186. He L,Pei H,Zhang C,Shao M,Li D,Tang M,Wang T,Chen X,Xiang M,Chen L. (2018) Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.. Eur J Med Chem, 145 (96-112). [PMID:29324347] [10.1016/j.ejmech.2017.12.079]
187. Ding X,Stasi LP,Ho MH,Zhao B,Wang H,Long K,Xu Q,Sang Y,Sun C,Hu H,Yu H,Wan Z,Wang L,Edge C,Liu Q,Li Y,Dong K,Guan X,Tattersall FD,Reith AD,Ren F. (2018) Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors.. Bioorg Med Chem Lett, 28 (9.0): (1615-1620). [PMID:29588215] [10.1016/j.bmcl.2018.03.045]
188. Elwaie TA,Abbas SE,Aly EI,George RF,Ali H,Kraiouchkine N,Abdelwahed KS,Fandy TE,El Sayed KA,Abd Elmageed ZY,Ali HI. (2020) HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability.. J Med Chem, 63 (24.0): (15906-15945). [PMID:33314925] [10.1021/acs.jmedchem.0c01647]
189. Zhao L,Fan T,Shi Z,Ding C,Zhang C,Yuan Z,Sun Q,Tan C,Chu B,Jiang Y. (2021) Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR mutant cell lines.. Eur J Med Chem, 213 (113173-113173). [PMID:33493830] [10.1016/j.ejmech.2021.113173]
190. Lamie PF,El-Kalaawy AM,Abdel Latif NS,Rashed LA,Philoppes JN. (2021) Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.. Eur J Med Chem, 214 (113222-113222). [PMID:33545637] [10.1016/j.ejmech.2021.113222]
191. Zhang CH,Chen K,Jiao Y,Li LL,Li YP,Zhang RJ,Zheng MW,Zhong L,Huang SZ,Song CL,Lin WT,Yang J,Xiang R,Peng B,Han JH,Lu GW,Wei YQ,Yang SY. (2016) From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.. J Med Chem, 59 (21.0): (9788-9805). [PMID:27739679] [10.1021/acs.jmedchem.6b00943]
192. Yang J,Chen K,Zhang G,Yang QY,Li YS,Huang SZ,Wang YL,Yang W,Jiang XJ,Yan HX,Zhu JQ,Xiang R,Luo YF,Li WM,Wei YQ,Li LL,Yang SY. (2018) Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.. Eur J Med Chem, 143 (1148-1164). [PMID:29133048] [10.1016/j.ejmech.2017.09.018]
193. Pang H,Wang N,Chai J,Wang X,Zhang Y,Bi Z,Wu W,He G. (2020) Discovery of novel TNNI3K inhibitor suppresses pyroptosis and apoptosis in murine myocardial infarction injury.. Eur J Med Chem, 197 (112314-112314). [PMID:32344181] [10.1016/j.ejmech.2020.112314]
194. Lakkaniga NR,Zhang L,Belachew B,Gunaganti N,Frett B,Li HY. (2020) Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression.. Eur J Med Chem, 203 (112589-112589). [PMID:32717530] [10.1016/j.ejmech.2020.112589]
195. Singh SS, Mattheolabakis G, Gu X, Withers S, Dahal A, Jois S.. (2021) A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models.. Eur J Med Chem, 216 (113312-113312). [PMID:33667849] [10.1016/j.ejmech.2021.113312]
196. King, C R CR, Kraus, M H MH and Aaronson, S A SA.. (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma.. Science (New York, N.Y.), (6): [PMID:2992089]
197. Semba, K K, Kamata, N N, Toyoshima, K K and Yamamoto, T T.. (1985) A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2995967]
198. Coussens, L L and 9 more authors.. (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.. Science (New York, N.Y.), (6): [PMID:2999974]
199. Yamamoto, T T and 7 more authors.. (1986) Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.. Nature, [PMID:3003577]
200. Tal, M M and 5 more authors.. (1987) Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation.. Molecular and cellular biology, [PMID:3039351]
201. Ehsani, A A, Low, J J, Wallace, R B RB and Wu, A M AM.. (1993) Characterization of a new allele of the human ERBB2 gene by allele-specific competition hybridization.. Genomics, [PMID:8095488]
202. Sarkar, F H FH, Ball, D E DE, Li, Y W YW and Crissman, J D JD.. (1993) Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2) gene.. DNA and cell biology, [PMID:8104414]
203. Olayioye, M A MA, Beuvink, I I, Horsch, K K, Daly, J M JM and Hynes, N E NE.. (1999) ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases.. The Journal of biological chemistry, (11): [PMID:10358079]
204. Kuhns, J J JJ, Batalia, M A MA, Yan, S S and Collins, E J EJ.. (1999) Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide.. The Journal of biological chemistry, (17): [PMID:10593938]
205. Arcaro, A A and 5 more authors.. (2000) Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors.. Molecular and cellular biology, [PMID:10805725]
206. Treish, I I, Schwartz, R R and Lindley, C C.. (2000) Pharmacology and therapeutic use of trastuzumab in breast cancer.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, (15): [PMID:11098307]
207. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ.. (2002) TTD: Therapeutic Target Database.. Nucleic acids research, (1): [PMID:11752352]
208. Birrane, Gabriel G, Chung, Judy J and Ladias, John A A JA.. (2003) Novel mode of ligand recognition by the Erbin PDZ domain.. The Journal of biological chemistry, (17): [PMID:12444095]
209. Li, Yongqing Y and 7 more authors.. (2003) Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein.. Molecular cancer research : MCR, [PMID:12939402]
210. Ivancic, Monika M, Daly, Roger J RJ and Lyons, Barbara A BA.. (2003) Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex and structural basis for Grb7 binding to ErbB2.. Journal of biomolecular NMR, [PMID:12975581]
211. Xia, Wenle W, Liu, Lei-Hua LH, Ho, Peter P and Spector, Neil L NL.. (2004) Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.. Oncogene, (22): [PMID:14737100]
212. Zhou, Hong H and 5 more authors.. (2004) Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.. International journal of radiation oncology, biology, physics, (1): [PMID:14751502]
213. and Langer, Corey J CJ.. (2004) Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.. International journal of radiation oncology, biology, physics, (1): [PMID:14967461]
214. Marone, Romina R and 5 more authors.. (2004) Memo mediates ErbB2-driven cell motility.. Nature cell biology, [PMID:15156151]
215. and Burris, Howard A HA.. (2004) Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.. The oncologist, [PMID:15163842]
216. Swiercz, Jakub M JM, Kuner, Rohini R and Offermanns, Stefan S.. (2004) Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2.. The Journal of cell biology, (21): [PMID:15210733]
217. Wang, Shao-Chun SC and 11 more authors.. (2004) Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2.. Cancer cell, [PMID:15380516]
218. Stephens, Philip P and 59 more authors.. (2004) Lung cancer: intragenic ERBB2 kinase mutations in tumours.. Nature, (30): [PMID:15457249]
219. Giri, Dipak K DK and 7 more authors.. (2005) Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor.. Molecular and cellular biology, [PMID:16314522]
220. Anido, Judit J and 6 more authors.. (2006) Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.. The EMBO journal, (12): [PMID:16794579]
221. Johnston, Stephen R D SR and Leary, Alex A.. (2006) Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.. Drugs of today (Barcelona, Spain : 1998), [PMID:16894399]
222. Farhan, Hesso H and 9 more authors.. (2006) Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen.. The Journal of pharmacology and experimental therapeutics, [PMID:16963623]
223. Olsen, Jesper V JV and 6 more authors.. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.. Cell, (3): [PMID:17081983]
224. Deng, Suhua S and 11 more authors.. (2007) Plexin-B2, but not Plexin-B1, critically modulates neuronal migration and patterning of the developing nervous system in vivo.. The Journal of neuroscience : the official journal of the Society for Neuroscience, (6): [PMID:17554007]
225. Lin, Amy A and Rugo, Hope S HS.. (2007) The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.. Current treatment options in oncology, [PMID:17660958]
226. Dephoure, Noah N and 6 more authors.. (2008) A quantitative atlas of mitotic phosphorylation.. Proceedings of the National Academy of Sciences of the United States of America, (5): [PMID:18669648]
227. Levêque, Dominique D, Gigou, Luc L and Bergerat, Jean Pierre JP.. (2008) Clinical pharmacology of trastuzumab.. Current clinical pharmacology, [PMID:18690878]
228. Daub, Henrik H and 9 more authors.. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.. Molecular cell, (8): [PMID:18691976]
229. Xiang, Bin B and 8 more authors.. (2008) Brk is coamplified with ErbB2 to promote proliferation in breast cancer.. Proceedings of the National Academy of Sciences of the United States of America, (26): [PMID:18719096]
230. Medina, Patrick J PJ and Goodin, Susan S.. (2008) Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.. Clinical therapeutics, [PMID:18803986]
231. Hawthorne, Valerie S VS and 5 more authors.. (2009) ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.. Molecular cancer research : MCR, [PMID:19372587]
232. Heinrich, C C and 9 more authors.. (2010) Copine-III interacts with ErbB2 and promotes tumor cell migration.. Oncogene, (18): [PMID:20010870]
233. Olsen, Jesper V JV and 11 more authors.. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.. Science signaling, (12): [PMID:20068231]
234. Tevaarwerk, Amye J AJ and Kolesar, Jill M JM.. (2009) Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.. Clinical therapeutics, [PMID:20110044]
235. Vazquez-Martin, Alejandro A and 5 more authors.. (2011) Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.. Journal of cellular physiology, [PMID:20658522]
236. Eigenbrot, Charles C, Ultsch, Mark M, Dubnovitsky, Anatoly A, Abrahmsén, Lars L and Härd, Torleif T.. (2010) Structural basis for high-affinity HER2 receptor binding by an engineered protein.. Proceedings of the National Academy of Sciences of the United States of America, (24): [PMID:20696930]
237. Zaoui, Kossay K, Benseddik, Khedidja K, Daou, Pascale P, Salaün, Danièle D and Badache, Ali A.. (2010) ErbB2 receptor controls microtubule capture by recruiting ACF7 to the plasma membrane of migrating cells.. Proceedings of the National Academy of Sciences of the United States of America, (26): [PMID:20937854]
238. Zang, Zhi Jiang ZJ and 18 more authors.. (2011) Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing.. Cancer research, (1): [PMID:21097718]
239. Kharmate, Geetanjali G and 6 more authors.. (2011) Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in the presence of somatostatin receptor 5 modulate signaling pathways.. Endocrinology, [PMID:21190959]
240. Rigbolt, Kristoffer T G KT and 9 more authors.. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.. Science signaling, (15): [PMID:21406692]
241. Li, Long-Yuan LY and 14 more authors.. (2011) Nuclear ErbB2 enhances translation and cell growth by activating transcription of ribosomal RNA genes.. Cancer research, (15): [PMID:21555369]
242. Zhou, Houjiang H and 6 more authors.. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome.. Journal of proteome research, (4): [PMID:23186163]
243. Barginear, Myra F MF, John, Veena V and Budman, Daniel R DR.. (2013) Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.. Molecular medicine (Cambridge, Mass.), (22): [PMID:23196784]
244. Bian, Yangyang Y and 9 more authors.. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.. Journal of proteomics, (16): [PMID:24275569]
245. Corominas, Roser R and 29 more authors.. (2014) Protein interaction network of alternatively spliced isoforms from brain links genetic risk factors for autism.. Nature communications, (11): [PMID:24722188]
246. Prince, Thomas L TL and 13 more authors.. (2015) Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.. PloS one, [PMID:26517842]
247. Li, Hui H and 18 more authors.. (2016) Crystal Structure and Substrate Specificity of PTPN12.. Cell reports, (10): [PMID:27134172]
248. Borges, Virginia F VF and 13 more authors.. (2018) Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.. JAMA oncology, (1): [PMID:29955792]
249. Tam, Constantine Si Lun CSL and 20 more authors.. (2019) Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.. Blood, (24): [PMID:31340982]
250. Li, Hui and 11 more authors.. (2020) SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane.. Journal of experimental & clinical cancer research : CR, (7): [PMID:32381043]
251. Le, Thuy-Linh and 36 more authors.. (2021) Dysregulation of the NRG1-ERBB pathway causes a developmental disorder with gastrointestinal dysmotility in humans.. The Journal of clinical investigation, (26): [PMID:33497358]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.

SKU	Size	Availability	Price
P412000-100μg	100μg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$39.90
P412000-1mg	1mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$159.90
P412000-5mg	5mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$664.90
P412000-10mg	10mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$1,196.90

Pertuzumab (anti-HER2), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to ERBB2/HER2/CD340, >95%, high purity, Human IgG1, Antibody of erb-b2 receptor tyrosine kinase 2

Basic Description

Product Properties

Images

Associated Targets(Human)

Mechanisms of Action

Database links

Certificates

Certificate of Analysis(COA)

Related Documents

FAQs and Articles

References

Solution Calculators

Molarity Calculator

Dilution Calculator

Reconstitution Calculator